IMBiologics Corp.

Based in South Korea, IMBiologics develops innovative immunomodulatory antibody therapeutics that aim to restore homeostasis and treat inflammatory and autoimmune diseases. IMBiologics, founded in 2020 in Suwon, South Korea, focuses on the development of immunomodulatory therapeutics. The company has raised a total of KRW 1,140. 000 mn across several funding rounds, with the latest being a Series B round of KRW 20 billion on July 24, 2023, backed by investors such as Ard Partners and CJ Investment.

The founder's history is not widely available, and the company does not have known subsidiaries. IMBiologics specializes in the research and development of innovative immunomodulatory antibody therapeutics aimed at restoring homeostasis in human health. The company’s flagship product, a bispecific antibody known as IMB-101 (NAV-240), targets both OX40L and TNFα, addressing inflammatory and autoimmune diseases such as hidradenitis suppurativa (HS), Crohn's disease, and ulcerative colitis. IMB-101 is designed to regulate inflammatory cytokines and adaptive immune responses, contributing to long-term immune balance.

Leveraging advanced technologies in antibody discovery and bispecific antibody development, IMBiologics plans to bring these therapeutics to various international markets, including the U. S. and Europe. The primary customers for these therapeutics include healthcare providers, pharmaceutical companies, and research institutions that specialize in treating chronic inflammatory conditions and other related disorders.

IMBiologics operates through a model that encompasses licensing agreements and clinical trial partnerships, generating revenue from collaborations with other pharmaceutical companies and biotech firms. The structure of these transactions typically involves upfront licensing fees, milestone payments tied to clinical development achievements, and potential royalties based on product sales once market approval is obtained. For instance, the partnership with Navigator Medicines for IMB-101 is set to facilitate a Phase 1b clinical trial, suggesting a collaborative approach to advancing product development. While specific pricing plans for their products are not disclosed, the revenue generated from these collaborations plays a significant role in supporting the company’s ongoing research and operational expenditures.

In July 2023, IMBiologics raised KRW 20 billion in Series B funding to support the conduct of Phase I clinical trials for the IMB-101 bispecific antibody and to develop immuno-oncology drugs based on ePENDY technology. The company aims to expand into international markets, focusing on the U. S. and Europe over the next few years, utilizing the recent funding to accelerate these initiatives.